Cantabio Pharmaceuticals Inc. (CTBO) Financial Statements (2024 and earlier)

Company Profile

Business Address 2225 EAST BAYSHORE ROAD
PALO ALTO, CA 94303
State of Incorp. DE
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments32,27552,110 4,56716,654
Cash and cash equivalents32,27552,110 4,56716,654
Prepaid expense 1,248   
Prepaid expense and other current assets12,500
Total current assets:33,52352,110 4,56729,154
Noncurrent Assets
Other undisclosed assets     1,000
TOTAL ASSETS:33,52352,110 4,56730,154
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:377,893225,49818,5846,63314,300
Accrued liabilities140,142173,41418,5846,63314,300
Other undisclosed accounts payable and accrued liabilities237,75152,084   
Debt322,256    
Due to related parties47,15422,9828,804 1,387
Other undisclosed current liabilities140,142173,414   
Total current liabilities:887,445421,89427,3886,63315,687
Noncurrent Liabilities
Total liabilities:887,445421,89427,3886,63315,687
Equity
Equity, attributable to parent(853,922)(369,784)(27,388)(2,066)14,467
Common stock26,80526,8054,8504,8503,650
Common stock, value, subscriptions1,060,000500,000 
Additional paid in capital167,32499,324113,467113,46744,350
Accumulated deficit(2,108,051)(995,913)(145,705)(120,383)(33,533)
Total equity:(853,922)(369,784)(27,388)(2,066)14,467
TOTAL LIABILITIES AND EQUITY:33,52352,110 4,56730,154

Income Statement (P&L) (USD)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Gross profit:  (32,000)   
Operating expenses(1,788,228)(1,532,715)(25,322)(86,850)(26,582)
Other undisclosed operating income    16,1323,828
Operating loss:(1,788,228)(1,564,715)(25,322)(86,850)(26,582)
Nonoperating income (expense)25,131(18,267)   
Loss, foreign currency transaction, before tax  (18,275)   
Debt instrument, convertible, beneficial conversion feature68,000    
Other nonoperating income (expense)(42,869)8   
Interest and debt expense(39,869)107,884   
Loss from continuing operations before income taxes:(1,802,966)(1,475,098)(25,322)(86,850)(26,582)
Income tax expense (benefit)    (9,038)
Loss from continuing operations:(1,802,966)(1,475,098)(25,322)(86,850)(35,620)
Loss before gain (loss) on sale of properties:(1,802,966)(1,475,098)(25,322)(86,850)(35,620)
Net loss:(1,802,966)(1,475,098)(25,322)(86,850)(35,620)
Other undisclosed net income attributable to parent690,828723,770  9,038
Net loss available to common stockholders, diluted:(1,112,138)(751,328)(25,322)(86,850)(26,582)

Comprehensive Income (USD)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Net loss:(1,802,966)(1,475,098)(25,322)(86,850)(35,620)
Comprehensive loss, net of tax, attributable to parent:(1,802,966)(1,475,098)(25,322)(86,850)(35,620)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: